UNI-EN 25:Current report 25 Medika AD above 30%
Firma: SOPHARMA ADSpis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| | UNI - EN REPORT No | 25 | / | 2015 | | ||||||
| Date of issue: | 2015-03-05 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| Current report 25 Medika AD above 30% | |||||||||||
| Official market - legal basis | |||||||||||
| Art. 160 ust 4 Ustawy o obrocie - informacja o transakcjach osуb maj№cych dostкp do informacji poufnych | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| Sopharma AD (the “Company") announces that on 5 March 2015 the Company bought 605 000 shares from the capital of Medika AD. After this transaction, the share of Sopharma AD in the capital of Medika AD increased to 30.42%. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| Current report 25 Medika AD above 30%.doc Current report 25 Medika AD above 30%.doc | Current report 25 Medika AD above 30% | ||||||||||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2015-03-05 | Ognian Donev | Executive director | |||
Cena akcji Sopharma
Cena akcji Sopharma w momencie publikacji komunikatu to 5.75 PLN. Sprawdź ile kosztuje akcja Sopharma aktualnie.
W tej sekcji znajdziesz wszystkie komunikaty ESPI EBI Sopharma.
